The receipt of a U.S. patent for Annamycin by Moleculin represents a significant milestone in the company's development pipeline, particularly for a drug targeting a critical unmet need in the treatment of Acute Myeloid Leukemia. This development not only enhances the company's intellectual property portfolio but also potentially increases its attractiveness to investors and partners interested in oncology and AML treatment solutions. The positive impact on Moleculin's stock price in the short term is likely due to increased investor confidence in the company's future revenue and growth prospects.